Addex Therapeutics (ADXN) announced that following the previously announced termination of development of ADX71149 in epilepsy, its partner Janssen Pharmaceuticals (JNJ) has returned all development and commercialization rights to ADX71149 and the partnership between the two companies has been terminated.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks